
GT Biopharma
GT Biopharma, a global biotech firm, develops innovative drugs for cancer, myeloma, and other medical needs.
- 8
- Public company
- San Francisco, CA, USUnited States

GT Biopharma, a global biotech firm, develops innovative drugs for cancer, myeloma, and other medical needs.
gtbiopharma.comCrawled Oct 15, 2026
GT Biopharma presents research orally at the **SITC 2026 Annual Meeting**, highlighting its immuno-oncology pipeline. The clinical-stage company develops therapies targeting cancer immunology. This recognition follows its ongoing trials in immuno-oncology treatments.
Oct 2026GlobeNewswireNews article
GT Biopharma Inc. (GTBP-Q) has regained compliance with Nasdaq’s minimum bid price requirements. The update follows a period where the stock price had fallen below Nasdaq’s threshold. The company operates in the biopharmaceutical sector, focusing on cancer immunotherapies.
Sep 2026The Globe and MailNews article
GT Biopharma secures FDA clearance for a new **investigator-sponsored trial (IST)** of **GTB-5550**, a **B7-H3-targeted natural killer (NK) cell engager**, now exploring its use in **multiple myeloma (MM)**. The company initiates a **Phase 1 trial** under the IST protocol to evaluate safety and efficacy in treating MM patients. GTB-5550 leverages NK cells to target B7-H3, a protein overexpressed in certain cancers.
Sep 2026GlobeNewswireNews article
GT Biopharma presents updates on its **TriKE® platform**, a clinical-stage immuno-oncology approach for cancer treatment. The company hosts a live event to detail progress in developing its proprietary technology. TriKE® leverages engineered immune cells to target tumors, with ongoing trials evaluating efficacy in solid and hematologic malignancies. Investors and researchers attend to learn about trial milestones and pipeline advancements.
Sep 2026GlobeNewswireNews article